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Change in the oestrogen receptor status of breast cancer with age -
comparison of two types of assay
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University Department ofSurgery, The Royal Infirmary, Edinburgh EH3 9YW, UK.
Summary The oestrogen receptor (ER) is considered to be an essential component of the mechanism of response of a breast tumour to endocrine therapy, but ER measurements have proved to have only modest predictive value. In the present study, we have examined ER status by both immunocytochemical assay (ER-ICA) on a fine needle aspirate and by radioligand-binding assay (DCC) on an excised portion of tumour. There was a correlation between the ER level detected by the two assays (Spearman's r = 0.77 for DCC versus ER-ICA staining intensity, r = 0.70 for DCC versus ER-ICA percentage of cells stained, P< 0.0001, n = 137 in each case). Each assay showed an increasing proportion of ER + ve results with increasing patient age. In the case of ER + ve tissues only, while ER concentration by DCC assay increased steadily with age (r = 0.39, P<0.0001, n = 108), the ER-ICA assay revealed that, staining intensity increased with age (r = 0.26, P = 0.001, n = 149) but the percentage of cells stained did not (r = 0.08, P = NS, n = 149). It is concluded that increasing endocrine responsiveness with advancing age could reflect the increasing proportion of ER + ve tumours with increased levels of ER per cell (as indicated by staining intensity) rather than increasing proportion of ER + ve cells.
Response to endocrine therapy depends, to a large extent, on
the presence or absence of oestrogen receptors (Lippman &
Allegra 1980; Manni et al., 1980; Furr & Jordan, 1984;
Hawkins 1985; Oriana et al., 1987). In addition, response and
oestrogen receptor status have both been reported to change
with age (Patterson et al., 1981; Beex & Koenders, 1984).
Receptor status can be quantified biochemically by the well
established radioligand-binding assay or the more recent
enzyme-immuno assay (ER-EIA). Using these methods, it
has been demonstrated that areas of individual tumours may
be heterogeneous for oestrogen receptor expression (Hawkins
et al., 1980; Crawford et al., 1987) as may individual lesions
in patients with metastatic disease (Hawkins et al., 1981;
King et al., 1982), so diminishing the ability of biochemical
assays to predict the overall response to endocrine therapy.
Biochemical assay of tumour cytosols fails to give any in-
formation about the cellularity of the lesion or the distribu-
tion of the oestrogen receptors at a cellular level. However,
by using the immunocytochemical assay (ER-ICA), the
localisation and degree of receptor expression can be
examined and we have previously demonstrated the impor-
tance of heterogeneity in determining whether a patient with
a receptor-positive tumour will benefit from treatment with
tamoxifen (Gaskell et al., 1989). This assay provides two
separate pieces of information, namely the intensity of stain-
ing and the proportion of cells stained. In the present paper,
we have examined the significance of each of these factors in
relation to the biochemical assay and to patient age.
Methods
An immunocytochemical assay for oestrogen receptor (ER-
ICA) was carried out on material obtained by fine needle
aspiration from 189 patients presenting to the Edinburgh
breast clinic with breast cancer. One hundred and thirty-
seven of these women underwent surgery, either as the
primary treatment (i.e. mastectomy or wide local excision) or
underwent wedge biopsy to allow biochemical assay of oes-
trogen receptors. The mean age of those patients was 67
years (35-86 years). The remainder (52) were treated with
tamoxifen without knowledge of their oestrogen receptor
status; their mean age was 77 years (70-95).
All patients underwent fine needle aspiration for diagnosis (Dixon et al., 1984) and the immunocytochemical assay was
carried out on cytospin preparations of the remaining mat-
erial, as we have described previously (Hawkins et al., 1988). In brief, control and test slides were assessed independently by two observers for (a) the percentage of cells stained and
(b) the intensity of that staining. The former represents the
mean of assessments from multiple fields (preferably > 100
cells per slide) and the latter was assessed on a subjective
scale of 0 (none), 1 (weak), 2 (moderate) and 3 (strong), this
being aided by reference to the Abbott Quality Control Slide
(individual cells mostly staining between 2 and 3), processed with each batch of aspirates. Allowance was made for any non-specific staining in the control slide (usually in the non-
malignant cells); a third cytospin preparation was made for
each aspirate, air-dried and stained with Giemsa, to provide
a check on the cytology.
When each of the two parameters was considered sep- arately for inter-observer agreement, the linear correlation
coefficients for the percentage of cells stained and the inten-
sity of staining were 0.957 and 0.930 respectively (n = 189,
data not shown). Assay precision (coefficients of variation)
was calculated using Snedecor's method (Snedecor, 1952)
considering the two observers' scores as duplicates; for per-
centage cells stained and intensity of staining it was 19.6%
and 17.2% respectively (n = 189, data not shown).
The tumours removed surgically were placed on ice and
representative portions were selected by the pathologist for
biochemical assay. The assays were carried out using our
standard dextran-coated charcoal assay (DCC) for oestrogen
receptors, based on competitive binding of a radioligand (tritiated oestradiol) and Scatchard analysis of the results
(Hawkins et al., 1975, 1981). The oestrogen receptor concen-
tration was calculated as fmol bound mg-' soluble protein. Tumours containing < 5 fmol mg-' soluble protein were con-
sidered oestrogen receptor-negative and those containing
> 5 fmol mg-' soluble protein were considered oestrogen
receptor-positive.
Results
Relationship ofstaining intensity to percentage ofcells staining
These two parameters were very strongly correlated (Spear- man's Rank correlation coefficient was 0.85, P<<0.0001).
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Relationship ofER-ICA staining to ER concentration by DCC
assay
Twenty-seven of 137 tumours were found to be oestrogen
receptor-negative when assayed by the DCC assay. Similarly,
40/189 tumours assayed by the ER-ICA assay showed no
evidence of immunocytochemical staining for oestrogen re-
ceptor protein. When the results obtained by the immunocy-
tochemical assay were compared with the oestrogen receptor
concentrations as determined by DCC, there was a good
correlation between the results of theDCC assay and the
observed intensity of staining (Spearman's Rank correlation
coefficient 0.77, P<0.0001, n = 137). When the tumours con-
sidered to be oestrogen receptor-positive (by DCC) were
considered separately the correlation was maintained, though
slightly less strongly (Spearman's Rank correlation coefficient
0.59, P<0.0001, n = 108). The second parameter, the per-
centage of cells staining, correlated less strongly with the
results of the DCC assay (Spearman's Rank correlation
coefficient 0.70, P<0.0001; for ER + ve tumours only,
Spearman's Rank correlation coefficient 0.47, P<0.001,
n = 108)). This correlation was not strengthened by combin-
ing the two parameters (% cells stained x intensity of stain-
ing) to produce a staining index (Spearman's Rank correla-
tion coefficients 0.71, P<0.0001, n = 108 and 0.51,
P<0.0001, n = 108 respectively).
Relationship between patient age and the ER status (DCC and
ER-ICA)
The proportion of oestrogen receptor-negative tumours (as
measured by DCC assay) fell steadily with increasing age
(Table I). There was a correlation between the median age of
the women with oestrogen-positive breast cancers, when they
were grouped by decade and the oestrogen receptor concen-
trations measured in their tumours (Spearman's Rank cor-
relation coefficient 0.39, P<0.0001, n = 108, Figure 1).
Similarly, the proportion of tumours failing to show immun-
ocytochemical staining for oestrogen receptor protein fell
with increasing age (Table I). Figures 2 and 3 show the
relationship between the patient's age and the results of the
ER-ICA assay. The intensity of staining correlated moder-
ately well with increasing age (Spearman's Rank correlation
coefficient 0.26, P = 0.0001, n = 149), but for the oestrogen
receptor-positive (staining) tumours the percentage of cells
stained did not alter significantly with age (Spearman's Rank
correlation coefficients 0.08, P = not significant).
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Figure 1 Relationship between the age of the patient, (grouped
by decade) and oestrogen receptor concentration measured in the
breast cancer cytosol using the radioligand binding assay. Spear-
man's Rank correlation coefficient was 0.37, P<0.0001, for 108
oestrogen receptor-positive tumours. - medians indicated by a
horizontal bar.
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Figure 2 Absence of significant relationship between the age of
the patient (grouped by decade) and oestrogen receptor status as
assessed by the percentage ofcells stained immunocytochemically.
Spearman's Rank correlation coefficient was 0.08, P = NS, for
149 breast cancers staining for the oestrogen receptor protein.
- medians indicated by a horizontal bar.
Discussion
Inter-relationships between the assays (Table II)
In the present study, we found that each of the parameters of
the ER-ICA assay (percentage cells stained, staining intensity
and staining index) showed a good correlation with the
results of the biochemical assay. However, three of 29
tumours showing no biochemical evidence of ER-protein
showed some immunocytochemical staining and conversely
Table I Proportion of oestrogen receptor-negative tumours for
patients grouped according to agedecade
Receptor negative Receptornegative
by DCCassay by ER-ICA assay
Age (<5fmolmg-'protein) (nostaining)
31-40 6/11 (55%) 7/11 (64%)
41-50 8/27 (30%) 9/27 (38%)
51 -60 11/45 (24%) 11/45 (24%)
61-70 4/46 (9%) 4/50 (8%)
71-80 0/7 (0%) 8/42 (19%)
81-90 0/1 1/13 (8%)
91 -100 0/1
Total 29/137 40/189
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Figure 3 Relationship between the age of the patient, grouped
by decade, and oestrogen receptor status as assessed by the
intensity of the immunocytochemical staining. Spearman's Rank
correlation coefficient was 0.26, P<0.001, for 149 breast cancers
staining for the oestrogen receptor protein. F - medians indi-
cated by a horizontal bar.
three of the 40 tumours with no evidence of immunocyto-
chemical staining on biochemical assay had significant amounts
of ER-protein (> 20 fmol mg-' protein). These findings are
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Table II Summary ofinter-relationships between theassaysandpatient age
Spearman's Rank
Spearman's Rank correlation coefficients
correlation coefficients forallER + ve tumours
Parameters foralltumoursassayed assayed
DCC vs ER-ICA stainingintensity - 0.77, P<0.000I (n = 137) 0.59, P<0.0001 (n = 108)
ER-ICA % cells stained - 0.70, P<0.0001 (n = 137) 0.47, P<0.0001 (n = 108)
ER-ICA staining index - 0.71, P<0.0001 (n = 137) 0.51, P<0.0001 (n = 108)
% cells stained vs ER-ICA stainingintensity - 0.85, P<0.0001 (n = 189) 0.61, P<0.0001 (n = 149)
Age vs DCC - 0.47, P<0.0001 (n = 137) 0.39, P<0.00001 (n = 108)
intensity ofstaining 0.34, P<0.0001 (n = 189) 0.26, P<0.0001 (n = 149)
% cells stained 0.24, P<0.0001 (n = 189) 0.08, P = not significant
in general agreement with those of other studies comparing
biochemical and immunohistochemical/immunocytochemical
assays for ER-protein (McCarty et al., 1986; Charpin et al.,
1986; Hawkins et al., 1986; Reiner et al., 1986; Weintraub et
al., 1987; Horsfall et al., 1989).
Relationships ofthe assays to age
In agreement with earlier workers (Allegra et al., 1979; Beex
& Koenders, 1984; Merecki & Jordan, 1985), we have
confirmed that breast cancers are more likely to be ER-
positive with increasing age and when ER-positive, to contain
higher concentrations of ER-protein. The two parameters of
the ER-ICA assay (intensity of staining and percentage of
cells stained) gave very different results, despite their clear
inter-relationship. Although the percentage of cells stained
correlated better with response to tamoxifen, as we have
previously reported (Gaskell et al., 1989), it was the intensity
of staining which had the better correlation with age (Spear-
man's Rank correlation coefficient 0.26, P = 0.001, n = 149).
These findings suggest that the two components of the
ER-ICA assay differ in their significance. As the patients get
older, the numbers of receptors per cell (intensity of staining)
increases, as reflected in the increase in biochemically detec-
ted ER concentration with age. Distribution of receptor (%
cells stained), however, failed to correlate with age and in our
experience and that of other investigators, this is the critical
factor in response to endocrine therapy (Pertschuk et al.,
1985, Coombes et al., 1987, Gaskell et al., 1989). Our
findings may therefore help to explain the difficulties exper-
ienced in relating clinical outcome to the absolute oestrogen
receptor concentration as measured biochemically in cytosol-
based assays (Howat et al., 1983). Tumours containing only a
small proportion of cells which stain intensely for ER protein
may prove to be relatively resistant to endocrine therapy
despite high concentrations of ER protein being detected
biochemically; biochemical assays do not take account of
tumour cellularity and heterogeneity, as indicated previously
by Horsfall et al. (1989) using video image analysis of the
nuclear optical densities.
Conclusion
These data may help to explain why apparently oestrogen
receptor-rich breast cancers can fail to respond to endocrine
therapy. It is the number of receptors per cell (as indicated
by the intensity of staining) which (i) correlates best with the
biochemically measured oestrogen receptor level and (ii)
changes most with age. However, it is the number (propor-
tion) of receptor-positive cells in a tumour which determines
the likelihood of response. This has particular implications
for the elderly, where some very high oestrogen receptor
concentrations detected biochemically may be of no greater
clinical significance than moderate levels detected in younger
women.
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